SANDOZ PRIVATE LIMITED

A randomized, double-blind, placebo-controlled clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 mcg and BREO® ELLIPTA® 100 mcg/25 mcg in participants with asthma